Results 81 to 90 of about 1,653 (153)

Editorial: Novel Applications of Stereotactic Body Radiotherapy (SBRT)

Frontiers in Oncology, 2021
Rupesh Kotecha, Rupesh Kotecha, Debnarayan Dutta, Rakesh Jalali, Alexander Muacevic   +4 more
doaj   +1 more source

sj-jpg-5-tam-10.1177_17588359231156387 – Supplemental material for Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC

, 2023
Supplemental material, sj-jpg-5-tam-10.1177_17588359231156387 for Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC by Wendi Xuzhang, Huayan Huang, Yongfeng Yu, Lan Shen, Ziming Li and Shun ...
Yongfeng Yu (5883800), Lan Shen (381473), Huayan Huang (8067056), Ziming Li (402892), Wendi Xuzhang (14719390), Shun Lu (402894)   +5 more
core   +1 more source

Outcomes of Radiotherapy in Oligoprogressive Breast Cancer

Introduction: Radiotherapy (RT) shows potential for improving local control in cases of oligoprogressive metastatic breast cancer (mBC). This retrospective analysis aims to evaluate the advantages of RT in such a clinical scenario.
Silvia Chiesa, Angela Bucaro, Armando Orlandi, Cynthia Aristei, Emilio Bria, Alejandro M. Sanchez, Gianluca Franceschini, Giovanna Garufi, Fabio Marazzi, Riccardo Masetti, Calogero Casa, Vincenzo Valentini, Valeria Masiello, Alba Di Leone, Maria A. Gambacorta, Alessandra Fabi, Giampaolo Tortora, Luca Tagliaferri, Francesca Moschella, Flavia De Lauretis, Ciro Mazzarella, Niccolo Borghesan   +21 more
core   +1 more source

sj-jpg-7-tam-10.1177_17588359231156387 – Supplemental material for Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC

, 2023
Supplemental material, sj-jpg-7-tam-10.1177_17588359231156387 for Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC by Wendi Xuzhang, Huayan Huang, Yongfeng Yu, Lan Shen, Ziming Li and Shun ...
Yongfeng Yu (5883800), Lan Shen (381473), Huayan Huang (8067056), Ziming Li (402892), Wendi Xuzhang (14719390), Shun Lu (402894)   +5 more
core   +1 more source

A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done

, 2021
Objective: In this review, we aim to collect and discuss available data about the role and composition of tumor microenvironment (TME) in oligometastatic (OMD) and oligoprogressive (OPD) non-small cell lung cancer (NSCLC).
Dodi, Alessandra, Caldart, Alberto, Pilotto, Sara, Milella, Michele, Kadrija, Dzenete, Belluomini, Lorenzo, Sposito, Marco, Casali, Miriam, Sartori, Giulia, Ferrara, Miriam Grazia, Bria, Emilio, Menis, Jessica, Avancini, Alice   +12 more
core   +1 more source

Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation

, 2022
Objective: To study whether delivering definitive radiotherapy (RT) to sites of oligoprogression in metastatic renal cell carcinoma (mRCC) enabled deferral of systemic therapy (ST) changes without compromising disease control or survival.
Tang, Chad, Jose A. Karam, Andrew J. Bishop, Nizar M. Tannir, Jonasch, Eric, Amishi Y. Shah, Yeboa, Debra N, Christopher G. Wood, Campbell, Matthew T, Chad Tang, Wang, Jennifer, Brian De, Aradhana M. Venkatesan, Jing Li, Zurita-Saavedra, Amado J, Wood, Christopher G, Amol J. Ghia, Matthew T. Campbell, Debra N. Yeboa, Nguyen, Quynh-Nhu, Matin, Surena F, Karam, Jose A, Venkatesan, Aradhana M, Jennifer Wang, Bishop, Andrew J, Pavlos Msaouel, Surena F. Matin, Li, Jing, Shah, Amishi Y, Eric Jonasch, Msaouel, Pavlos, Quynh‐Nhu Nguyen, Ghia, Amol J, De, Brian, Amado J. Zurita‐Saavedra, Tannir, Nizar M   +35 more
core   +1 more source

Management of oligometastatic and oligoprogressive epidermal growth factor receptor mutated non-small cell lung cancer patients: state of the art of a combined approach

Exploration of Targeted Anti-tumor Therapy
Recently, the development of targeted therapy approaches such as those based on tyrosine kinase inhibitor (TKI) greatly improved the clinical outcomes of patients affected by oncogene addicted advanced non-small cell lung cancer (NSCLC).
Francesca Di Pressa, Fabiana Perrone, Anna Benini, Frank Lohr, Marcello Tiseo, Alessio Bruni   +5 more
doaj   +1 more source

Local Therapy for Isolated Central Nervous System Progression Among Patients Receiving Antibody-Drug Conjugate Therapy

Advances in Radiation Oncology
Purpose: Antibody drug conjugates (ADCs) are an increasingly important class of therapeutics among patients with breast, lung, urothelial, and other malignancies.
Emily S. Lebow, MD, Jordan Eichholz, MS, Zhigang Zhang, PhD, Nicolas Toumbacaris, MSPH, Brandon Imber, MD, MA, Linda Chen, MD, Quincey LaPlant, MD, PhD, Josh Yamada, MD, Luke R.G. Pike, MD, DPhil, Shanu Modi, MD, Andrew D. Seidman, MD, Kathryn Beal, MD, Nelson S. Moss, MD, Yao Yu, MD   +13 more
doaj   +1 more source

The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer

Cancer Medicine, 2018
Background Diagnoses of oligometastatic prostate cancer (PC) increased in the recent years thanks to the advancement in imaging and more effective systemic therapies.
Ciro Franzese, Paolo Andrea Zucali, Lucia Di Brina, Giuseppe D'Agostino, Pierina Navarria, Davide Franceschini, Armando Santoro, Marta Scorsetti   +7 more
doaj   +1 more source

Hold the line: Local control strategies in oligoprogressive gynecologic cancers during systemic therapy

International audienceGynecologic malignancies have undergone significant therapeutic advances with the introduction of targeted agents such as bevacizumab and poly(ADP-ribose) polymerase inhibitors (PARPis), immune checkpoint inhibitors, and, more ...
Durante, Stefano, Colombo, Nicoletta, Fagotti, Anna, Ray-Coquard, Isabelle, Caruso, Giuseppe, Lazzari, Roberta, Casaccia Giordano, Filippo, Jereczek-Fossa, Barbara Alicja, Macchia, Gabriella, Marchetti, Claudia   +9 more
core   +1 more source